Literature DB >> 12000616

Antibiotic exposure as a risk factor for emergence of resistance: the influence of concentration.

I M Gould1, F M MacKenzie.   

Abstract

Evolution of antibiotic resistance (AR) is increasingly perceived as a major clinical problem. The use of bactericidal antibiotics may protect against this, to some extent, by eradication of the pathogen, but the borders between cidal and inhibitory activity in the patient are often blurred. In addition, there are clinical reasons why eradication of the pathogen may not always be desirable. Antibiotic dosing schedules are currently driven by the perception that T >MIC and AUIC are the main predictors of outcome for time-dependent and concentration-dependent antibiotics, respectively. In the context of protecting against development of resistance in the pathogen however, peak antibiotic concentration and the concept of mutant prevention concentrations may be more important. The role of post-antibiotic and sub-MIC effects is more conjectural. Considerations of mechanisms of resistance and their relationship to antibiotic dosing schedules will also be highlighted. Lastly, the relevance of all this to the development of resistance in the normal bacterial flora will be discussed.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12000616

Source DB:  PubMed          Journal:  J Appl Microbiol        ISSN: 1364-5072            Impact factor:   3.772


  9 in total

1.  Continuous vs. intermittent cefotaxime administration in patients with chronic obstructive pulmonary disease and respiratory tract infections: pharmacokinetics/pharmacodynamics, bacterial susceptibility and clinical efficacy.

Authors:  A R H van Zanten; M Oudijk; M K E Nohlmans-Paulssen; Y G van der Meer; A R J Girbes; K H Polderman
Journal:  Br J Clin Pharmacol       Date:  2006-07-21       Impact factor: 4.335

2.  Evolution and recombination of the plasmidic qnr alleles.

Authors:  Mia H C Baquirin; Miriam Barlow
Journal:  J Mol Evol       Date:  2008-07-01       Impact factor: 2.395

3.  Role of lon, an ATP-dependent protease homolog, in resistance of Pseudomonas aeruginosa to ciprofloxacin.

Authors:  Michelle D Brazas; Elena B M Breidenstein; Joerg Overhage; Robert E W Hancock
Journal:  Antimicrob Agents Chemother       Date:  2007-09-24       Impact factor: 5.191

4.  Assessment of antibiotic resistance in Klebsiella pneumoniae exposed to sequential in vitro antibiotic treatments.

Authors:  Jeongjin Kim; Ara Jo; Ekachai Chukeatirote; Juhee Ahn
Journal:  Ann Clin Microbiol Antimicrob       Date:  2016-12-09       Impact factor: 3.944

5.  Targeted surveillance strategies for efficient detection of novel antibiotic resistance variants.

Authors:  Allison L Hicks; Stephen M Kissler; Tatum D Mortimer; Kevin C Ma; George Taiaroa; Melinda Ashcroft; Deborah A Williamson; Marc Lipsitch; Yonatan H Grad
Journal:  Elife       Date:  2020-06-30       Impact factor: 8.140

6.  Spatial structure undermines parasite suppression by gene drive cargo.

Authors:  James J Bull; Christopher H Remien; Richard Gomulkiewicz; Stephen M Krone
Journal:  PeerJ       Date:  2019-10-29       Impact factor: 2.984

7.  A Portable Device for the Generation of Drug-Loaded Three-Compartmental Fibers Containing Metronidazole and Iodine for Topical Application.

Authors:  Francis Brako; Chaojie Luo; Rupy Kaur Matharu; Lena Ciric; Anthony Harker; Mohan Edirisinghe; Duncan Q M Craig
Journal:  Pharmaceutics       Date:  2020-04-18       Impact factor: 6.321

8.  Hospital-based ciprofloxacin use evaluation in Eastern Ethiopia: a retrospective assessment of clinical practice.

Authors:  Tigist Gashaw Tekalign; Mekonnen Sisay Shiferaw; Tewodros Tesfa Hailegiyorgis; Yohannes Baye Embiale; Firehiwot Amare Abebe
Journal:  Pan Afr Med J       Date:  2021-01-19

9.  Association between antimicrobial drug class for treatment and retreatment of bovine respiratory disease (BRD) and frequency of resistant BRD pathogen isolation from veterinary diagnostic laboratory samples.

Authors:  Johann F Coetzee; Drew R Magstadt; Pritam K Sidhu; Lendie Follett; Adlai M Schuler; Adam C Krull; Vickie L Cooper; Terry J Engelken; Michael D Kleinhenz; Annette M O'Connor
Journal:  PLoS One       Date:  2019-12-13       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.